MALVERN, PA — Annovis Bio Inc. (NYSE: ANVS) has been granted a U.S. patent for the use of its leading compound, buntanetap, ...

Annovis Bio’s buntanetap receives US patent for treatment and prevention of acute brain or nerve injuries: Malvern, Pennsylvania Thursday, January 16, 2025, 17:00 Hrs [IST] Anno ...

Annovis Bio (ANVS) announced it was granted the U.S. patent covering methods for the treatment and prevention of acute brain ...

Jan. 15, 2025 — Scientists have come up with a drug that is a potential candidate for tackling memory deficits in the early stages of the disease in rodents. ... New Innovative Local Treatment ...

Annovis Bio, headquartered in Malvern, Pennsylvania, is committed to addressing neurodegeneration in diseases such as Alzheimer's and Parkinson's. The company is developing innovative therapies that ...

First subjects dosed in a Phase 2 trial of VTX3232 in participants with obesity and cardiometabolic risk factors, with topline data expected in H2 2025 Phase 2 trial of VTX2735 in participants with ...

Inc. (NYSE: ANVS) ("Annovis" or the "Company"), a late-stage clinical drug platform company pioneering transformative ...

Almost finished… We need to confirm your email address. To complete the subscription process, please click the link in the email we just sent you. Daily news – Get the most important news from ...

Analyst Jason McCarthy of Maxim Group maintained a Buy rating on Annovis Bio (ANVS – Research Report), retaining the price target of $25.00. Discover outperforming stocks and invest smarter with ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Maxim Group has recently raised Annovis Bio Inc (ANVS) stock to Buy rating, as announced on October 25, 2024, according to Finviz. Earlier, on December 29, 2023, Canaccord Genuity had initiated the ...

MALVERN, PA — Annovis Bio Inc. (NYSE: ANVS) has announced that the U.S. Food and Drug Administration (FDA) has accepted an updated protocol for the company’s pivotal Phase 3 Alzheimer’s (AD) ...